Edwards Lifesciences : 2024 Corporate Impact report
EW
Contents
Introduction 3
Letter from the CEO 4
Our Credo 5
Edwards at a Glance 6
2024 Corporate Impact Highlights 7
Patients First 9
Access to Healthcare 10
Patient Experience and Voice 14
Global Corporate Giving 16
Products 19
Product Safety and Quality 20
Product Design and Innovation 24
Our People 27
Human Capital Management 28
A Culture of Belonging 30
Our Planet 34
Environment, Health and Safety 35
Governance and Ethics 45
Supply Chain Management 46
Corporate Governance 52
Ethics and Compliance 56
Appendix 59
About this Report 60
ESG Materiality 60
Edwards Lifesciences is the global leader
in patient-focused medical innovations for structural heart disease. Driven by a passion to help patients, we collaborate with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives.
EDWARDS
2024 CORPORATE IMPACT REPORT
Introduction
Letter from the CEO
Transforming Patient Lives, Driving a Sustainable Future
Bringing innovation to patients is core to everything we do at Edwards. Our dedication to serving those with needs is the driving force of the impact we have on patients, society and our stakeholders. This commitment is further demonstrated through our comprehensive environmental, social and governance practices.
Edwards' leading business, transcatheter aortic valve replacement (TAVR), delivers profound value for patients, healthcare systems and society. This technology, backed by high-quality scientific evidence, has generated transformative benefits by improving survival, enhancing quality of life and optimizing healthcare resources. One analysis found that in 2020 alone, the net benefit of TAVR for those with symptomatic severe aortic stenosis (SSAS) in the U.S population was $43.4 billion, due to higher treatment rates, lower mortality and better quality of life.1
Charitable giving is another element of our impact, and it is at the heart of our culture at Edwards. I'm inspired by our efforts to improve the lives of underserved patients and strengthen our communities, and I'm proud that approximately 90 percent of our employees engaged in charitable activities that impacted nearly 50 countries supported by the Edwards Foundation. Thanks to their commitment, the Foundation and our philanthropic initiative, Every Heartbeat Matters, we and our global partners are on track to impact 2.5 million additional underserved structural heart patients by the end of 2025.
Every patient is an example of the deep impact we are making around the world. And I am committed to leading this effort with integrity, transparency and a focus on a better tomorrow for the patients and communities we serve.
Thank you for your continued support.
Bernard J. Zovighian I Chief Executive Officer
1 J.P. Sevilla, et. al, 2022 Journal of Medical Economics, Cost-utility and cost-benefit analysis of TAVR availability in the US severe symptomatic aortic stenosis patient population.
Our Credo
At Edwards Lifesciences, we are dedicated to providing innovative solutions for people fighting cardiovascular disease.
Through our actions, we will become trusted partners with customers, colleagues, and patients - creating a community unified in its mission to improve the quality of life around the world. Our results will benefit customers, patients, employees, and shareholders.
We will celebrate our successes, thrive on discovery, and continually expand our boundaries. We will act boldly, decisively, and with determination on behalf of people fighting cardiovascular disease.
Helping patients is our life's work, and
Edwards at a Glance
Through breakthrough technologies, world-class evidence and partnerships with healthcare ecosystem, we are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most.
2024 Corporate Impact Highlights
We are proud to focus on creating positive impacts that benefit our patients throughout everything we do. In addition to the accomplishments listed below, please see our 2024 Annual Report and 2025 Proxy Statement for more information about progress in 2024.
Key Accomplishments in 2024
All new employees completed Code of Conduct training within 60 days of start date
100% Complete
99% of targeted workforce completed Code of Conduct survey and certification, indicating understanding of company policies, procedures and best practices
100% Complete
All global employees completed unconscious bias training, and new hires completed the training within six months of employment EARLY TAVR groundbreaking results published in New England Journal of Medicine revealing great success in treating patients with asymptomatic aortic stenosis
2024 Corporate Impact Highlights
In Progress Remove Barriers
along the patient journey to continuously increase treatment rates for all indicated severe aortic stenosis (AS) patients
Raise awareness and launch new therapies
treating the "forgotten" tricuspid valve, enabling access to life changing treatment option for patients with severe tricuspid regurgitation (TR)
Collaborative
patient engagement
Ensure that our therapies are addressing the needs of patients through an increasingly collaborative patient engagement process
Reduce
our environmental footprint according to Edwards' Environment, Health and Safety (EHS) plan from a 2020 base year by 2025:
Empower
and activate patients
by meaningfully increasing awareness of structural heart disease globally by 2024
20% Reduction
in waste generation intensity
10% Reduction
in water withdrawal intensity
Drive Edwards' aspiration of 100%
global employee participation in charitable activity as measured by the Employee Engagement survey
Improve the lives of 2.5 million
additional underserved structural heart and critical care patients through the (EHM) initiative by the end of 2025
51.6% Reduction
Reduce Scope 3 greenhouse gas emissions 51.6% per USD of value added from a 2021 base year by 2030
Patients First
Patients First
At Edwards Lifesciences, our unwavering commitment to putting patients first drives everything we do. We are dedicated to transforming patient lives with breakthrough medical technologies and passionate engagement that strengthens our communities. By prioritizing patient needs, we strive to break down barriers to treatment, ensure access to high-quality care and support the well-being of communities worldwide. Our mission is to make a meaningful difference in the lives of patients and their families, every day.
Access to Healthcare
We believe all patients deserve access to innovative, valuable and high-quality care. Edwards' approach to access to healthcare focuses on providing quality cardiovascular care to underserved and marginalized patients by addressing regulatory, geographic and economic barriers, offering access to new therapies, contributing to public policy, donating technologies for humanitarian care, supporting charitable organizations in improving clinical expertise and patient care in low- and middle-income countries and developing products and services that enhance patient care. Through these efforts, we contribute to long-term well-being of our communities and our company.
Improving Access to Care
To help improve access to care, we design programs focused on addressing the structural heart disease burdens, disparities and obstacles keeping patients from reaching appropriate treatment. Developing a data-backed understanding of which population segments are at the greatest risk for developing aortic stenosis (AS) and which groups are historically underserved regarding treatment provides us with the opportunity to develop more impactful, targeted outreach efforts.
The following metrics specific to AS patients illustrate several treatment burdens and patient access gaps:
• 1.3 to 1.6 million Americans aged 65 and older have AS.2
• Up to 50% of patients with AS will die within two years after the onset of symptoms if they do not receive an aortic valve replacement (AVR).3
• Less than 50% of patients with an indication or potential indication for AVR received AVR.4
• Black patients with SSAS have been historically less likely to receive AVR than white patients.5
• Women are 9% less likely to receive AVR than men.6
2 Owens et al., 2021 Heart 107 (18): 1493-1502
3 Leon et al., 2010 N EnglJ Med363 1597-1607
4 Li et al., 2022 J Am Coll Cardiol79 (9): 864-877
5 Brennan et al., 2020 J Am Heart Assoc 9 (16): e015879
6
Lowensternet al., 2021. Am Heart J 237 116-126
10
Disclaimer
Edwards Lifesciences Corporation published this content on March 27, 2025, and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 27, 2025 at 22:24:05.481.